
|Articles|October 11, 2022
The Role of Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
A select group of hematologic oncologists participated in a virtual workshop to discuss the role of BTK inhibitors in the treatment of MCL and CLL Led by Kami Maddocks, MD; and Anthony Mato, MD. The expert panel shared insights on the available evidence regarding BTK inhibitors in MCL and CLL, novel treatment approaches, and optimal strategies for combining and sequencing therapies.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
5




































